(NASDAQ: KRYS) Krystal Biotech's forecast annual revenue growth rate of 104.18% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Krystal Biotech's revenue in 2024 is $50,699,000.On average, 4 Wall Street analysts forecast KRYS's revenue for 2024 to be $6,728,040,670, with the lowest KRYS revenue forecast at $5,036,085,648, and the highest KRYS revenue forecast at $8,250,126,826. On average, 3 Wall Street analysts forecast KRYS's revenue for 2025 to be $9,920,324,826, with the lowest KRYS revenue forecast at $7,101,446,616, and the highest KRYS revenue forecast at $11,662,216,315.
In 2026, KRYS is forecast to generate $12,018,873,032 in revenue, with the lowest revenue forecast at $8,326,516,889 and the highest revenue forecast at $14,089,722,768.